Complete Filing Data
NeuroSense Therapeutics Ltd. reported General And Administrative Expense of $4.86 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean NeuroSense Therapeutics Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income * | -$11.1M | -$10.2M | -$10.1M | -$10.5M | -$4.0M | -$2.8M | -$1.2M |
| General And Administrative Expense | $4.9M | $4.2M | $4.8M | $5.0M | $2.5M | $393.0K | $337.0K |
| Research And Development Expense | $6.2M | $5.7M | $7.3M | $5.6M | |||
| Profit Loss From Operating Activities | -$13.3M | -$13.6M | -$5.6M | -$2.9M | -$1.2M | ||
| Comprehensive Income | -$11.3M | -$12.3M | -$4.0M | -$2.8M | -$1.2M | ||
| Operating Income Loss | -$11.1M | -$9.9M | -$12.0M | -$10.6M | |||
| Nonoperating Income Expense | -$40.0K | -$308.0K | $1.9M | $62.0K | |||
| Research And Developments Expenses | $7.6M | $6.4M | $3.1M | $2.5M | $898.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$1.6M | $2.6M | -$1.8M | $5.8M | $10.8M | |||
| Liabilities | $2.6M | $2.0M | $4.9M | $2.1M | $2.4M | $120.0K | ||
| Equity | -$1.6M | $2.6M | -$1.8M | $5.8M | $10.8M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $166.0K | $3.4M | $2.6M | $3.5M | $11.1M | |||
| Cash And Cash Equivalents | $2.6M | $3.5M | $11.1M | $699.0K | $895.0K | $86.0K | ||
| Assets | $1.0M | $4.6M | $3.2M | $7.7M | $11.4M | $779.0K | ||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $29.0K | $70.0K | $17.0K | $9.0K | $7.0K | |||
| Increase In Other Receivables | -$19.0K | -$55.0K | $204.0K | $12.0K | $3.0K | |||
| Cash Flows From Used In Operating Activities | -$8.5M | -$7.6M | -$1.5M | -$695.0K | -$582.0K | |||
| Cash Flows From Used In Investing Activities | $3.6M | -$3.5M | -$17.0K | -$9.0K | -$26.0K | |||
| Cash Flows From Used In Financing Activities | $3.9M | $3.7M | $11.9M | $508.0K | $1.4M | |||
| Adjustments For Increase Decrease In Trade Account Payable | $961.0K | $459.0K | -$16.0K | $32.0K | $23.0K | |||
| Adjustments For Increase Decrease In Other Operating Payables | $928.0K | $236.0K | $493.0K | $51.0K | $9.0K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations | -$3.2M | $738.0K | -$903.0K | -$7.5M | ||||
| Trade And Other Current Payables To Trade Suppliers | $1.5M | $498.0K | $39.0K | $55.0K | ||||
| Shortterm Deposits Classified As Cash Equivalents | $40.0K | $36.0K | $39.0K | $37.0K | ||||
| Retained Earnings Accumulated Deficit | -$47.8M | -$36.7M | -$26.1M | |||||
| Retained Earnings | -$32.1M | -$20.8M | -$8.4M | -$4.4M | ||||
| Restricted Cash And Investments Noncurrent | $22.0K | $23.0K | $22.0K | |||||
| Restricted Cash And Investments Current | $47.0K | $35.0K | $40.0K | |||||
| Property Plant And Equipment Net | $58.0K | $66.0K | $85.0K | |||||
| Property Plant And Equipment | $85.0K | $77.0K | $19.0K | $13.0K | ||||
| Other Receivables Net Current | $565.0K | $989.0K | $236.0K | |||||
| Other Current Receivables | $236.0K | $255.0K | $310.0K | $30.0K | ||||
| Other Current Payables | $2.0M | $1.2M | $558.0K | $65.0K | ||||
| Operating Lease Right Of Use Asset | $170.0K | $84.0K | $162.0K | |||||
| Noncurrent Assets | $260.0K | $329.0K | $19.0K | $13.0K | ||||
| Liabilities Current | $2.5M | $2.0M | $3.5M | |||||
| Liabilities And Stockholders Equity | $1.0M | $4.6M | $3.2M | |||||
| Equity And Liabilities | $3.2M | $7.7M | $11.4M | $779.0K | ||||
| Current Liabilities | $3.5M | $1.7M | $597.0K | $120.0K | ||||
| Current Assets | $2.9M | $7.4M | $11.4M | $766.0K | ||||
| Cash And Cash Equivalents At Carrying Value | $166.0K | $3.4M | $2.6M | |||||
| Assets Noncurrent | $250.0K | $173.0K | $269.0K | |||||
| Assets Current | $778.0K | $4.4M | $2.9M | |||||
| Additional Paid In Capital Common Stock | $46.2M | $39.2M | $24.4M | |||||
| Accounts Payable Trade Current | $799.0K | $1.2M | $1.5M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Proceeds From Issuance Of Warrants | $4.5M | $11.3M | $4.3M | ||||
| Increase Decrease In Cash And Cash Equivalents | -$903.0K | -$7.5M | $10.4M | -$196.0K | $809.0K | ||
| Share Based Compensation | $2.1M | $557.0K | $1.5M | $1.7M | |||
| Payments To Acquire Property Plant And Equipment | $8.0K | $3.0K | $29.0K | $70.0K | |||
| Net Cash Provided By Used In Operating Activities | -$7.7M | -$10.1M | -$8.4M | -$7.6M | |||
| Net Cash Provided By Used In Investing Activities | -$8.0K | $1.0K | $3.5M | -$3.6M | |||
| Net Cash Provided By Used In Financing Activities | $4.4M | $10.9M | $4.0M | $3.8M | |||
| Increase Decrease In Other Accounts Payable | $1.3M | $262.0K | $928.0K | $606.0K | |||
| Increase Decrease In Accounts Payable Trade | -$361.0K | -$299.0K | $961.0K | $459.0K | |||
| Proceeds From Exercise Of Options | $5.0K | $3.9M | $1.2M | ||||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $8.0K | -$88.0K | $18.0K | ||||
| Proceeds From Stock Options Exercised | $22.0K | $5.0K | $3.9M | ||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $35.0K | -$41.0K | $8.0K | -$88.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Basic Earnings Loss Per Share | $-0.83 | $-1.07 | $-0.65 | $-0.51 | $-0.26 | ||
| Weighted Average Number Of Shares Outstanding Basic | 25.5M | 18.6M | 13.6M | 11.5M | |||
| Earnings Per Share Diluted | $-0.44 | $-0.54 | $-0.74 | $-0.91 | |||
| Earnings Per Share Basic | $-0.44 | $-0.54 | $-0.74 | $-0.91 | |||
| Diluted Earnings Loss Per Share | $-0.83 | $-1.07 | $-0.65 | $-0.51 | |||
| Weighted Average Number Of Diluted Shares Outstanding | 25.5M | 18.6M | 13.6M | 11.5M | |||
| Common Stock Shares Outstanding | 32.6M | 23.2M | 15.4M | ||||
| Common Stock Shares Issued | 32.6M | 23.2M | 15.4M | ||||
| Common Stock Shares Authorized | 90.0M | 90.0M | 60.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Increase Decrease Through Sharebased Payment Transactions | $3.0M | $4.7M | $4.7M | $2.1M | $611.0K | ||
| Finance Income Cost | $2.0M | $1.2M | $1.5M | $60.0K | $13.0K | ||
| Finance Income | $4.2M | $1.3M | $2.7M | $61.0K | $18.0K | ||
| Finance Costs | $2.2M | $45.0K | $1.2M | $1.0K | $5.0K | ||
| Finance Expense Income | -$402.0K | $24.0K | -$791.0K | $2.0K | |||
| Depreciation | $16.0K | $22.0K | $21.0K | $12.0K | |||
| Adjustments For Depreciation Expense | $97.0K | $89.0K | $3.0K | $3.0K | |||
| Decrease In Operating Right Of Use Asset | $84.0K | $78.0K | $74.0K | $70.0K | |||
| Adjustments For Sharebased Payments | $2.8M | $5.1M | $4.2M | $2.1M | $611.0K | ||
| Adjustments For Fair Value Gains Losses | -$4.0M | -$1.2M | -$2.7M | ||||
| Share Premium | $30.2M | $26.4M | $17.5M | $5.1M | |||
| Noncurrent Government Grants | $1.5M | $218.0K | $1.8M |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 9, 2026.